Design Therapeutics (DSGN) EBIT (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly EBIT of -$22.2 million for Q2 2026, down 2.82% year-over-year from -$22.8 million in Q2 2025, and down 12.54% on a QoQ basis from -$19.7 million in Q1 2026.
Design Therapeutics (DSGN) EBIT (2020 - 2026) Analysis & Trends
Design Therapeutics has reported EBIT for 7 years, with the latest figure at -$22.2 million in Q2 2026.
- EBIT for Q2 2026 came in at -$22.2 million, down 2.82% year-over-year; the trailing twelve-month figure through Jun 2026 was -$79.4 million (down 5.92% YoY), and the FY2025 annual result was -$79.5 million, down 27.39% from the prior year.
- EBIT eased to -$22.2 million in Q2 2026, from -$19.7 million in the prior quarter.
- Over five years, EBIT peaked at -$13.4 million in Q1 2022 and troughed at -$22.6 million in Q2 2023.
- A 5-year average of -$18.3 million and a median of -$19.0 million in 2022 frame the typical range for EBIT.
- The widest annual swing landed in 2022, when EBIT sank 135.39%; it then jumped 33.49% in 2024.
- A 5-year view of EBIT shows it stood at -$19.4 million in 2022, then increased by 22.02% to -$15.1 million in 2023, then decreased by 10.4% to -$16.7 million in 2024, then retreated by 8.84% to -$18.2 million in 2025, then declined by 22.06% to -$22.2 million in 2026.
- Per Business Quant data, the three most recent EBIT figures were -$22.2 million in Q2 2026, -$19.7 million in Q1 2026, and -$18.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -22.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.18 Mn |
| Mar 31, 2026 | -19.71 Mn |
| Dec 31, 2025 | -18.17 Mn |
| Sep 30, 2025 | -19.31 Mn |
| Jun 30, 2025 | -21.57 Mn |
| Mar 31, 2025 | -20.42 Mn |
| Dec 31, 2024 | -16.69 Mn |
| Sep 30, 2024 | -16.25 Mn |
| Jun 30, 2024 | -15.04 Mn |
| Mar 31, 2024 | -14.40 Mn |
| Dec 31, 2023 | -15.12 Mn |
| Sep 30, 2023 | -18.82 Mn |
| Jun 30, 2023 | -22.60 Mn |
| Mar 31, 2023 | -21.65 Mn |
| Dec 31, 2022 | -19.39 Mn |
| Sep 30, 2022 | -19.19 Mn |
| Jun 30, 2022 | -15.64 Mn |
| Mar 31, 2022 | -13.37 Mn |
| Dec 31, 2021 | -11.13 Mn |
| Sep 30, 2021 | -11.34 Mn |